A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma

Clin Lymphoma. 2004 Sep;5(2):130-4. doi: 10.3816/clm.2004.n.020.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Arsenic Trioxide
  • Arsenicals / administration & dosage*
  • Arsenicals / adverse effects
  • Ascorbic Acid / administration & dosage*
  • Ascorbic Acid / adverse effects
  • Disease Progression
  • Drug Resistance, Neoplasm
  • Humans
  • Melphalan / administration & dosage*
  • Melphalan / adverse effects
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Oxides / administration & dosage*
  • Oxides / adverse effects
  • Prospective Studies
  • Recurrence
  • Time Factors
  • Treatment Outcome

Substances

  • Arsenicals
  • Oxides
  • Ascorbic Acid
  • Melphalan
  • Arsenic Trioxide